MORPHINE SULFATE INJECTION USP SOLUTION

Država: Kanada

Jezik: angleščina

Source: Health Canada

Aktivna sestavina:

MORPHINE SULFATE

Dostopno od:

STERINOVA INC.

Koda artikla:

N02AA01

INN (mednarodno ime):

MORPHINE

Odmerek:

100MG

Farmacevtska oblika:

SOLUTION

Sestava:

MORPHINE SULFATE 100MG

Pot uporabe:

INTRAVENOUS

Enote v paketu:

15G/50G

Tip zastaranja:

Narcotic (CDSA I)

Terapevtsko območje:

OPIATE AGONISTS

Povzetek izdelek:

Active ingredient group (AIG) number: 0104545004; AHFS:

Status dovoljenje:

APPROVED

Datum dovoljenje:

2019-08-29

Lastnosti izdelka

_N_
_Morphine Sulfate Injection USP_
_Page 1 of 31 _
_Page_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
MORPHINE SULFATE INJECTION USP
Sterile Solution
1 mg/mL
Narcotic Analgesic
Sterinova Inc.
Date of Revision: Aug. 21, 2023
3005 Avenue Jose-Maria-Rosell
Saint-Hyacinthe, QC
J2S 0J9
Submission Control No: 273709
_N_
_Morphine Sulfate Injection USP_
_Page 2 of 31 _
_Page_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................................
3
SUMMARY PRODUCT INFORMATION
..............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................
3
WARNINGS AND PRECAUTIONS
.......................................................................................................
4
ADVERSE REACTIONS
.......................................................................................................................
12
DRUG INTERACTIONS
........................................................................................................................
14
DOSAGE AND
ADMINISTRATION....................................................................................................
15
OVERDOSAGE
......................................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................
20
STORAGE AND STABILITY
...............................................................................................................
21
SPECIAL HANDLING INSTRUCTIONS
.............................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.........